Clinical Trial Update: Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma. [Phase 3]

View source ↗

Summary

Phase 3 trial comparing CC-5013 to placebo in metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• CC-5013 (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Melanoma, Neoplasm Metastasis | Phase 3 | Status: COMPLETED